Published in Br J Pharmacol on November 08, 2004
Renal hypoxia and dysoxia after reperfusion of the ischemic kidney. Mol Med (2008) 1.72
Emerging roles for platelets as immune and inflammatory cells. Blood (2014) 1.56
Role of platelets in neuroinflammation: a wide-angle perspective. J Neuroinflammation (2010) 1.11
Leukocyte cell surface proteinases: regulation of expression, functions, and mechanisms of surface localization. Int J Biochem Cell Biol (2008) 0.96
Neutrophil granulocyte-dependent proteolysis enhances platelet adhesion to the arterial wall under high-shear flow. J Thromb Haemost (2010) 0.92
The role of matrix metalloproteinases 2 and 9 during rat tongue carcinogenesis induced by 4-nitroquinoline 1-oxide. J Mol Histol (2010) 0.84
Role of Platelet-Derived Microvesicles As Crosstalk Mediators in Atherothrombosis and Future Pharmacology Targets: A Link between Inflammation, Atherosclerosis, and Thrombosis. Front Pharmacol (2016) 0.76
URIC ACID AND TISSUE REPAIR. Arq Bras Cir Dig (2015) 0.75
Pharmacological characterization of nanoparticle-induced platelet microaggregation using quartz crystal microbalance with dissipation: comparison with light aggregometry. Int J Nanomedicine (2015) 0.75
Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol (1987) 5.23
Granules of the human neutrophilic polymorphonuclear leukocyte. Blood (1997) 5.07
Proteinase-activated receptors. Pharmacol Rev (2001) 5.02
The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol (1987) 4.88
Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol (1995) 4.36
Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med (2002) 4.02
An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A (1990) 3.98
PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell (1989) 3.95
Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science (2000) 3.75
Synthesis of nitric oxide from L-arginine by neutrophils. Release and interaction with superoxide anion. Biochem J (1989) 3.70
Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest (1999) 3.16
Nitric oxide release from a single cell measured in situ by a porphyrinic-based microsensor. Nature (1992) 3.14
An improved method for washing of human platelets with prostacyclin. Thromb Res (1983) 3.07
Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol (2001) 2.66
The microcirculation and inflammation: modulation of leukocyte-endothelial cell adhesion. J Leukoc Biol (1994) 2.54
The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. J Exp Med (2002) 2.42
S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br J Pharmacol (1992) 2.39
Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med (2000) 2.31
cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci U S A (1996) 2.17
MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells. Exp Cell Res (2001) 2.12
Outside-in signals delivered by matrix metalloproteinase-1 regulate platelet function. Circ Res (2002) 2.10
Role of blood platelets in infection and inflammation. J Interferon Cytokine Res (2002) 2.01
Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. Eur J Biochem (2003) 1.93
Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res (1999) 1.78
Structure-function relationships in the activation of platelet thrombin receptors by receptor-derived peptides. J Biol Chem (1992) 1.74
Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain (2003) 1.67
Release of gelatinase A during platelet activation mediates aggregation. Nature (1997) 1.65
Cardiac surgery increases the activity of matrix metalloproteinases and nitric oxide synthase in human hearts. J Thorac Cardiovasc Surg (2001) 1.55
Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factor. J Clin Invest (1997) 1.49
Metalloproteinase inhibitors improve the recovery and hemostatic function of in vitro-aged or -injured mouse platelets. Blood (2003) 1.49
Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2. Thromb Haemost (1999) 1.43
Characterization of the L-arginine:nitric oxide pathway in human platelets. Br J Pharmacol (1990) 1.36
Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase. J Biol Chem (2001) 1.35
Hydrolysis of triple-helical collagen peptide models by matrix metalloproteinases. J Biol Chem (2000) 1.35
Leukolysin/MMP25/MT6-MMP: a novel matrix metalloproteinase specifically expressed in the leukocyte lineage. Cell Res (1999) 1.34
Activated platelets induce superoxide anion release by monocytes and neutrophils through P-selectin (CD62). J Immunol (1993) 1.22
Venous levels of shear support neutrophil-platelet adhesion and neutrophil aggregation in blood via P-selectin and beta2-integrin. Circulation (1998) 1.20
Leukocyte integrins and inflammation. Cell Mol Life Sci (1998) 1.19
Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide. Cancer Res (2001) 1.18
Direct electrochemical measurement of nitric oxide released from human platelets. Biochem Biophys Res Commun (1993) 1.15
Platelet release of trimolecular complex components MT1-MMP/TIMP2/MMP2: involvement in MMP2 activation and platelet aggregation. Blood (2000) 1.12
The role of nitric oxide and metalloproteinases in the pathogenesis of hyperoxia-induced lung injury in newborn rats. Br J Pharmacol (1998) 1.12
Leukocyte-leukocyte interactions mediated by platelet microparticles under flow. Blood (2000) 1.11
Platelet activation by polymorphonuclear leukocytes exposed to chemotactic agents. Am J Physiol (1990) 1.08
Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: role of receptor glycoproteins. Br J Pharmacol (2003) 1.08
Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human platelets. Br J Pharmacol (2002) 1.08
Localization and translocation of MMP-2 during aggregation of human platelets. Thromb Haemost (1998) 1.07
Mechanisms of action of proteinase-activated receptor agonists on human platelets. Br J Pharmacol (2002) 1.07
Structure and function of P-selectin glycoprotein ligand-1. Leuk Lymphoma (1998) 1.06
Nonremodeling properties of matrix metalloproteinases: the platelet connection. Circ Res (2002) 1.01
Matrix metalloproteinase inhibition. From the Jurassic to the third millennium. Ann N Y Acad Sci (1999) 1.01
Platelet microparticles promote platelet interaction with subendothelial matrix in a glycoprotein IIb/IIIa-dependent mechanism. Circulation (1999) 0.96
Polarized release of matrix metalloproteinase-2 and -9 from cultured human placental syncytiotrophoblasts. Biol Reprod (2000) 0.95
Differential release of matrix metalloproteinase-9 and nitric oxide following infusion of endotoxin to human volunteers. Acta Anaesthesiol Scand (2003) 0.93
Procoagulant activity and active calpain in platelet-derived microparticles. Thromb Res (1996) 0.92
Structural analysis of the alpha(2) integrin I domain/procollagenase-1 (matrix metalloproteinase-1) interaction. J Biol Chem (2001) 0.90
Pharmacological characteristics of solid-phase von Willebrand factor in human platelets. Br J Pharmacol (2001) 0.90
Nitric oxide and cyclic GMP increase the expression of matrix metalloproteinase-9 in vascular smooth muscle. J Pharmacol Exp Ther (2003) 0.90
Platelet-dependent primary hemostasis promotes selectin- and integrin-mediated neutrophil adhesion to damaged endothelium under flow conditions. Blood (1996) 0.88
Matrix metalloproteinase-2 in platelet adhesion to fibrinogen: interactions with nitric oxide. Med Sci Monit (2001) 0.86
Platelet associated fibrinogen and ICAM-2 induce firm adhesion of neutrophils under flow conditions. Thromb Haemost (1998) 0.86
Rational optimization of a short human P-selectin-binding peptide leads to nanomolar affinity antagonists. J Biol Chem (2003) 0.83
Nitric oxide and superoxide detection in human platelets. Methods Enzymol (1999) 0.79
Effects of ovariectomy on aggregation, secretion, and metalloproteinases in porcine platelets. Am J Physiol Heart Circ Physiol (2003) 0.79
Increased matrix metalloproteinase activity after canine cardiopulmonary bypass is suppressed by a nitric oxide scavenger. J Thorac Cardiovasc Surg (2003) 0.78
Platelet adherence to isolated rat hepatic sinusoidal endothelial cells after cold preservation. Transplantation (2002) 0.77
Release of matrix metalloproteinase-9 during balloon angioplasty in patients with stable angina. A preliminary study. Int J Cardiol (2003) 0.76
Avastin doesn't blind people, people blind people. Am J Ophthalmol (2012) 3.15
Extracorporeal life support. BMJ (2010) 2.61
Nanoparticle-induced platelet aggregation and vascular thrombosis. Br J Pharmacol (2005) 2.56
Race-specific differences in endothelial function: predisposition of African Americans to vascular diseases. Circulation (2004) 1.98
Platelet--cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol (2004) 1.76
Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9. Circ Res (2008) 1.67
Role of nitric oxide, nitroxidative and oxidative stress in wound healing. Pharmacol Rep (2005) 1.54
Nanoparticle adhesion to the cell membrane and its effect on nanoparticle uptake efficiency. J Am Chem Soc (2013) 1.44
Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation (2003) 1.36
Role of matrix metalloproteinases in intestinal inflammation. J Pharmacol Exp Ther (2006) 1.34
Distribution of nitric oxide synthase in normal and cirrhotic human liver. Proc Natl Acad Sci U S A (2002) 1.33
Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol (2012) 1.31
Leptin-induced endothelial dysfunction in obesity. Am J Physiol Heart Circ Physiol (2008) 1.30
Increased activity and expression of matrix metalloproteinase-9 in a rat model of distal colitis. Am J Physiol Gastrointest Liver Physiol (2002) 1.18
Angiotensin-(1-7)-Stimulated Nitric Oxide and Superoxide Release From Endothelial Cells. Hypertension (2001) 1.17
Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells. Eur J Cancer (2013) 1.16
Role of metalloproteinases in platelet function. Thromb Res (2007) 1.14
Isolation of exosomes for subsequent mRNA, MicroRNA, and protein profiling. Methods Mol Biol (2011) 1.14
Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy (2008) 1.12
Re: Impact of Macula-off Retinal Detachment on Visual Outcome, A Systematic Review and Meta-Analysis of Literature. Retina (2015) 1.09
Off-label drug use: the bevacizumab story. Mayo Clin Proc (2013) 1.09
Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension (2002) 1.09
Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: role of receptor glycoproteins. Br J Pharmacol (2003) 1.08
To the Editor. Retina (2014) 1.08
c-Jun N-terminal kinase 2 deficiency protects against hypercholesterolemia-induced endothelial dysfunction and oxidative stress. Circulation (2008) 1.08
Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human platelets. Br J Pharmacol (2002) 1.08
Mechanisms of action of proteinase-activated receptor agonists on human platelets. Br J Pharmacol (2002) 1.07
Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation (2005) 1.07
Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug. Br J Ophthalmol (2012) 1.06
The nitric oxide-endothelin-1 connection. Heart Fail Rev (2003) 1.06
Re: Bilateral same-day intravitreal injections using a single vial and molecular bacterial screening for safety surveillance. Retina (2013) 1.06
Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation (2002) 1.06
Selectins--potential pharmacological targets? Drug Discov Today (2006) 1.05
AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension (2002) 1.05
Amorphous silica nanoparticles trigger nitric oxide/peroxynitrite imbalance in human endothelial cells: inflammatory and cytotoxic effects. Int J Nanomedicine (2011) 1.04
Aflibercept. Nat Rev Drug Discov (2012) 1.04
Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder. Biol Psychiatry (2004) 1.03
Matrix metalloproteinase-9 modulates intestinal injury in rats with transmural colitis. J Leukoc Biol (2006) 1.03
Nonremodeling properties of matrix metalloproteinases: the platelet connection. Circ Res (2002) 1.01
S-nitroso human serum albumin treatment reduces ischemia/reperfusion injury in skeletal muscle via nitric oxide release. Circulation (2002) 1.01
Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats. J Cardiovasc Pharmacol (2012) 1.00
Deletion of the activated protein-1 transcription factor JunD induces oxidative stress and accelerates age-related endothelial dysfunction. Circulation (2013) 0.99
Re-engineering the operating room using variability methodology to improve health care value. J Am Coll Surg (2013) 0.97
Generation and role of angiostatin in human platelets. Blood (2003) 0.95
Ultraviolet B light-induced nitric oxide/peroxynitrite imbalance in keratinocytes--implications for apoptosis and necrosis. Photochem Photobiol (2010) 0.95
Amorphous silica nanoparticles aggregate human platelets: potential implications for vascular homeostasis. Int J Nanomedicine (2012) 0.95
Adverse balance of nitric oxide/peroxynitrite in the dysfunctional endothelium can be reversed by statins. J Cardiovasc Pharmacol (2007) 0.94
The nonthiazolidinedione PPARgamma agonist L-796,449 is neuroprotective in experimental stroke. J Neuropathol Exp Neurol (2005) 0.94
Platelet aggregation-induced by caco-2 cells: regulation by matrix metalloproteinase-2 and adenosine diphosphate. J Pharmacol Exp Ther (2006) 0.93
Involvement of nitric oxide in angiogenic activities of vascular endothelial growth factor isoforms. Growth Factors (2004) 0.92
Endophthalmitis is not a "never event". Ophthalmology (2012) 0.92
Endothelial NADH/NADPH-dependent enzymatic sources of superoxide production: relationship to endothelial dysfunction. Acta Biochim Pol (2004) 0.91
Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK. Cell Cycle (2008) 0.91
Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity. J Cardiovasc Pharmacol (2006) 0.90
Nitric oxide and cyclic GMP increase the expression of matrix metalloproteinase-9 in vascular smooth muscle. J Pharmacol Exp Ther (2003) 0.90
Drug delivery techniques for treating age-related macular degeneration. Expert Opin Drug Deliv (2013) 0.90
Protein kinase C delta mediates platelet-induced breast cancer cell invasion. J Pharmacol Exp Ther (2006) 0.89
Nitric oxide-matrix metaloproteinase-9 interactions: biological and pharmacological significance--NO and MMP-9 interactions. Biochim Biophys Acta (2014) 0.89
S-nitroso human serum albumin reduces ischaemia/reperfusion injury in the pig heart after unprotected warm ischaemia. Cardiovasc Res (2007) 0.88
Nitric oxide, platelet function, myocardial infarction and reperfusion therapies. Heart Fail Rev (2003) 0.88
Alteration of decreased plasma NO metabolites and platelet NO synthase activity by paroxetine in depressed patients. Neuropsychopharmacology (2006) 0.87
Dynamics of nitric oxide release in the cardiovascular system. Acta Biochim Pol (2003) 0.87
Loss of arterial and renal nitric oxide bioavailability in hypertensive rats with diabetes: effect of beta-blockers. Am J Hypertens (2009) 0.87
Hypoxia results in upregulation and de novo activation of von Willebrand factor expression in lung endothelial cells. Arterioscler Thromb Vasc Biol (2013) 0.86
Mechanisms of toxicity of amorphous silica nanoparticles on human lung submucosal cells in vitro: protective effects of fisetin. Chem Res Toxicol (2012) 0.86
Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats. J Atheroscler Thromb (2011) 0.86
Synergistic effect of amlodipine and atorvastatin in reversing LDL-induced endothelial dysfunction. Pharm Res (2007) 0.86
Effect of aspirin on constitutive nitric oxide synthase and the biovailability of NO. Thromb Res (2003) 0.85
Outbreak of toxic anterior segment syndrome following cataract surgery associated with impurities in autoclave steam moisture. Infect Control Hosp Epidemiol (2006) 0.85
Platelet-associated angiogenesis regulating factors: a pharmacological perspective. Can J Physiol Pharmacol (2012) 0.85
Mechanisms of platelet-stimulated colon cancer invasion: role of clusterin and thrombospondin 1 in regulation of the P38MAPK-MMP-9 pathway. Carcinogenesis (2013) 0.85
Synergistic Antihypertensive Effects of Nifedipine on Endothelium : Concurrent Release of NO and Scavenging of Superoxide. Hypertension (2001) 0.85
Matrix metalloproteinase-2 contributes to increased platelet reactivity in patients with metastatic prostate cancer: a preliminary study. Thromb Res (2003) 0.84
Angiostatin inhibits endothelial MMP-2 and MMP-14 expression: a hypoxia specific mechanism of action. Vascul Pharmacol (2012) 0.84
Effects of dextroamphetamine, lithium chloride, sodium valproate and carbamazepine on intraplatelet Ca2+ levels. J Psychiatry Neurosci (2003) 0.83
Neurorepair versus neuroprotection in stroke. Cerebrovasc Dis (2006) 0.83
Tyrosine phosphatase beta regulates angiopoietin-Tie2 signaling in human endothelial cells. Angiogenesis (2009) 0.83
Novel astaxanthin prodrug (CDX-085) attenuates thrombosis in a mouse model. Thromb Res (2010) 0.83
Fisetin prevents fluoride- and dexamethasone-induced oxidative damage in osteoblast and hippocampal cells. Food Chem Toxicol (2011) 0.82
Combined L-arginine and antioxidative vitamin treatment mollifies ischemia-reperfusion injury of skeletal muscle. J Vasc Surg (2004) 0.82
Electropolymerization on microelectrodes: functionalization technique for selective protein and DNA conjugation. Anal Chem (2006) 0.82